How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD
about
How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD
description
scientific article published on 01 August 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2018
@uk
name
How ibrutinib, a B-cell malign ...... steroid-resistant chronic GVHD
@en
How ibrutinib, a B-cell malign ...... steroid-resistant chronic GVHD
@nl
type
label
How ibrutinib, a B-cell malign ...... steroid-resistant chronic GVHD
@en
How ibrutinib, a B-cell malign ...... steroid-resistant chronic GVHD
@nl
prefLabel
How ibrutinib, a B-cell malign ...... steroid-resistant chronic GVHD
@en
How ibrutinib, a B-cell malign ...... steroid-resistant chronic GVHD
@nl
P2860
P1476
How ibrutinib, a B-cell malign ...... steroid-resistant chronic GVHD
@en
P2093
Bruce R Blazar
Samantha M Jaglowski
P2860
P304
P356
10.1182/BLOODADVANCES.2018013060
P407
P577
2018-08-01T00:00:00Z